Interestingly, ceramide synthases and their derivatives modulate ER stress and NAFLD progression by regulating SREBP-1 cleavage, via decreased levels of INSIG-1, providing another therapeutic approach for NAFLD [54]. The gene discussed is TLCD3B; the disease is metabolic dysfunction-associated steatotic liver disease.